We are live on ! Find out more
AGMB

AgomAb Therapeutics NV
AGMB

34 hedge funds and large institutions have $337M invested in AgomAb Therapeutics NV in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more capital invested

Capital invested by funds: $245M → $337M (+$91.7M)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

6% more funds holding

Funds holding: 32 → 34 (+2)

4.78% more ownership

Funds ownership: 47.92% → 52.7% (+4.8%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
34
Holders Change
+2
Holders Change %
+6.25%
% of All Funds
0.41%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
4
Reduced
6
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$29M
2
NCM
Nantahala Capital Management
Connecticut
+$4.14M
3
O
OrbiMed
New York
+$2.17M
4
Aberdeen Group
Aberdeen Group
United Kingdom
+$1.57M
5
AA
ALPS Advisors
Colorado
+$563K

Top Sellers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
-$3.15M
2
SGM
Seven Grand Managers
New York
-$1.72M
3
Millennium Management
Millennium Management
New York
-$999K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$787K
5
LCM
Laurion Capital Management
New York
-$525K
Name Holding Trade Value Shares
Change 		Change in
Stake
XT
26
XTX Topco
Cayman Islands
$133K +$116K +10,271 New
Citigroup
27
Citigroup
New York
$123K +$107K +9,496 New
UBS Group
28
UBS Group
Switzerland
$27.6K -$48.5K -4,309 -67%
GI
29
GAMMA Investing
California
$17.4K +$15.1K +1,344 New
Morgan Stanley
30
Morgan Stanley
New York
$15.6K -$20.5K -1,825 -60%
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$9.79K +$8.49K +754 New
LFG
32
Larson Financial Group
Missouri
$9.06K +$7.86K +698 New
SS
33
SBI Securities
Japan
$26 – – –
CIAM
34
Caitong International Asset Management
Hong Kong
$26 +$23 +2 New
LP
35
LMR Partners
United Kingdom
– -$3.15M -300,000 Closed
Millennium Management
36
Millennium Management
New York
– -$999K -95,233 Closed
Alyeska Investment Group
37
Alyeska Investment Group
Illinois
– -$787K -75,000 Closed
LCM
38
Laurion Capital Management
New York
– -$525K -50,000 Closed
Citadel Advisors
39
Citadel Advisors
Florida
– -$367K -35,000 Closed
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
– -$161K -15,326 Closed
Jane Street
41
Jane Street
New York
– -$134K -12,794 Closed
1
2

AGMB Hedge Fund Activity: Q2 2026 in Review

34 of the 8,217 institutional investors tracked by Wall St. Rank reported a position in AgomAb Therapeutics NV (AGMB) for Q2 2026, worth a combined $337M — up 37% from $245M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new AGMB positions and 7 closed out — a net gain of 2 holders — while 4 added to existing stakes and 6 trimmed.

The largest buyer was Redmile Group, adding an estimated $29M. The largest seller was LMR Partners, exiting entirely with an estimated $3.15M sold.

  • 34 institutional investors held AgomAb Therapeutics NV (AGMB) as of Q2 2026, up from 32 in Q1 2026.
  • Funds reported $337M of AgomAb Therapeutics NV stock for Q2 2026, up 37% quarter-over-quarter.
  • 9 funds opened new AgomAb Therapeutics NV positions in Q2 2026 and 7 closed out, a net change of +2 holders.
  • The largest AgomAb Therapeutics NV buyer in Q2 2026 was Redmile Group, an estimated $29M added.
  • The largest AgomAb Therapeutics NV seller in Q2 2026 was LMR Partners, an estimated $3.15M sold.

Based on aggregated 13F filings for Q2 2026.